Recursion Pharmaceuticals
NasdaqGS:RXRX Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 90 Fair Values set on narratives written by author
AN
Consensus Narrative from 7 Analysts
REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success
Key Takeaways Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries. Strategic partnerships and operational synergies enhance cash flow, efficiencies, and computational capabilities, supporting robust future earnings growth.
View narrativeUS$9.00
FV
24.6% undervalued intrinsic discount45.25%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
3 days ago author updated this narrative